Nick Glattard is the co-founder and Chief Technology Officer of EnsoData
Nick Glattard is the co-founder and CTO of EnsoData, a medical software company pioneering the field of Waveform AI. EnsoData’s first product, EnsoSleep, is an FDA-cleared SaaS that aids in the diagnosis of sleep apnea for both in-lab and at-home tests. Cleared in 2024, EnsoSleep PPG expands the same diagnostic capabilities to FDA cleared pulse oximeters.
Under the combined leadership of Glattard and co-founders Sam Rusk and Chris Fernandez, EnsoData has grown to more than 50 full time employees, raised over $30,000,000 in venture capital funding from top VCs, obtained one of the first FDA clearances of AI/ML software in all of healthcare, and collaborated to release more than 30 AI research publications to push the science of sleep forward.
Through his work at EnsoData, more than 1.3M patients have received a fast, accurate sleep apnea diagnosis with EnsoSleep – a technology he pioneered that transforms billions of waveform data points collected during a sleep test into an easy-to-read report so their 500+ clinical users and 100+ provider organizations can make faster, more consistent diagnoses.
Nick Glattard’s work has earned him and EnsoData various recognitions, including being named to the 2021 Forbes 30 Under 30 in Healthcare list and the Inc. Best Places to Work list for the third year in a row (one of only three Wisconsin companies to make the list in 2023), and the Wisconsin Innovation Award in Healthcare, among other acknowledgments.
